We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Glucose Test in Pregnancy Can Detect CV Risk

By LabMedica International staff writers
Posted on 08 May 2019
Gestational diabetes has consistently been associated with an increased future risk of cardiovascular disease (CVD), regardless of the antepartum screening protocol or diagnostic criteria by which gestational diabetes is diagnosed.

Gestational diabetes is a condition in which a woman without diabetes develops high blood sugar levels during pregnancy. Gestational diabetes generally results in few symptoms; however, it does increase the risk of preeclampsia, depression, and requiring a Caesarean section.

Scientists associated with Sunnybrook Health Sciences Centre (Toronto, ON, Canada) carried out a retrospective population-based cohort study used administrative databases from the Ministry of Health and Long-Term Care of Ontario, Canada. The study enrolled all women in the Ontario database who had a 50-g oral glucose challenge test during pregnancy at between 24 and 28 weeks’ gestation and who delivered between July 2007 and December 2015.

Gestational diabetes was defined as 1-hour post-challenge plasma glucose concentration ≥11.1 mmol/L or a result between 7.8 and 11.0 mmol/L with a record of a diabetes diagnosis on the delivery hospital record. The participants were divided into six equal groups based on the glucose screening test results: ≤4.8 mmol/L; 4.9 to 5.5 mmol/L; 5.6 to 6.2 mmol/L; 6.3 to 6.9 mmol/L; 7.0 to 7.9 mmol/L; and ≥8.0 mmol/L. The primary study outcome was CV disease, including hospitalization for myocardial infarction, acute coronary syndrome, stroke, coronary artery bypass grafting, percutaneous coronary intervention, or carotid endarterectomy.

The scientists reported that of 259,164 women who underwent a screening glucose challenge in pregnancy, gestational diabetes was documented in 13,609 women (5.3%). Over a median follow-up of almost 4 years, 138 CV disease events were recorded in the study population. There was a positive association between 1-hour post-challenge glucose concentration and the likelihood of a CV event; each 1 mmol/L increase in glucose concentration was associated with a 13% higher risk for CV disease (adjusted hazard ratio [HR], 1.13). The association remained significant even after the exclusion of twin and multiple gestation pregnancies (HR, 1.13).

In the group of women without gestational diabetes, CV risk was higher in patients with an abnormal glucose screening test (≥7.8 mmol/L), but there was also increased CV risk in patients with a glucose concentration at the upper end of the normal range (7.2-7.7 mmol/L) compared with ≤7.1 mmol/L (HR, 1.94; and HR, 1.65, respectively). The authors concluded that the relationship between gestational glycaemia and subsequent risk of cardiovascular disease extends into the normo-glycemic range. Accordingly, glucose screening in pregnancy could identify future risk of cardiovascular disease in women who do not have gestational diabetes. The study was published on May 1, 2019, in the journal Lancet Diabetes Endocrinology.

Related Links:
Sunnybrook Health Sciences Centre


Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Community-Acquired Pneumonia Test
RIDA UNITY CAP Bac
New
Centrifuge
Hematocrit Centrifuge 7511M4
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The experimental blood test accurately indicates severity and predicts potential recovery from spinal cord injury (Photo courtesy of 123RF)

Blood Test Identifies Multiple Biomarkers for Rapid Diagnosis of Spinal Cord Injury

The National Institutes of Health estimates that 18,000 individuals in the United States sustain spinal cord injuries (SCIs) annually, resulting in a staggering financial burden of over USD 9.... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more

Industry

view channel
Image: Tumor-associated macrophages visualized using the Multiomic LS Assay (Photo courtesy of ACD)

Leica Biosystems and Bio-Techne Expand Spatial Multiomic Collaboration

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded the longstanding partnership between its spatial biology brand, Advanced Cell Diagnostics (ACD, Newark, CA, USA), and Leica Biosystems (Nussloch,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.